Trials / Unknown
UnknownNCT02142010
Weekly Paclitaxel Liposome Injection Plus Cisplatin in Preoperative Treatment of Breast Cancer
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 67 (estimated)
- Sponsor
- Nanjing Luye Sike Pharmaceutical Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the pathological complete response (pCR) rate in breast cancer patients treated with weekly paclitaxel liposome injection plus cisplatin preoperative regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | paclitaxel liposome injection plus cisplatin | Paclitaxel liposome injection 80 mg/m2, given on days 1, 8,15 and 22 of a 28-day cycle. Cisplatin 25 mg/m2, given on days 1, 8 and 15 of a 28-day cycle, for 4 cycles(4 months) |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2015-06-01
- First posted
- 2014-05-20
- Last updated
- 2014-08-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02142010. Inclusion in this directory is not an endorsement.